The data from a phase I/II multicenter study (NCT02716116) showed that among advanced EGFR ex20ins mutant NSCLC patients who had previously received containing platinum chemotherapy, the ORR receiving mobocertinib (160 mg/d) was 43%, the median DOR was 13.9 months, the DCR was 86%, and the median PFS was 7.3 months (19). Here, EGFR is linked to non-small cell lung carcinoma.